Creative Medical Technology Holdings, Inc.
CELZ
NASDAQ·Healthcare·Biotechnology·Mkt cap $2.3M
$0.90
▼ -2.13%
P/E
—
Mkt Cap
$2.3M
52-Wk Range
$0.62–$6.25
52-Week Range
$0.62 - $6.25
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 73.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary adult stem cell technology platform across multiple therapeutic areas
- Diversified product pipeline reducing single-product dependency risk
- First-mover advantage in specific regenerative medicine indications
- Experienced management team in biotechnology and regenerative medicine
Bear Case
1 risk
- Above-average volatility (beta 1.9).
Growth
Stable outlook
Expansion of clinical trials and regulatory approvals for pipeline products
Value
Valuation data unavailable
Momentum
Weak
-17.4% over 3m
Quality
Below
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying CELZ right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 6, 2026
AUG 7, 2026
Reported EPS of -$0.41 vs -$0.39 consensus (-5.1% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-5.1%
Revenue trend · last 8Q
—
—
—
-100%
—
0%
-100%
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$3.0K
$3.0K
$0
$0
$3.0K
$0
$0
Margins · last 8Q
Gross
—
Profit
—
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Roth Capital · Aug 20, 2026
vs Industry
How CELZ stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related